These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32355835)

  • 21. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
    Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis.
    See LC; Lee HF; Chao TF; Li PR; Liu JR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; Lip GYH
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):975-986. PubMed ID: 33211254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and Safety of Under or Over-dosing of Direct Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-analysis of 148909 Patients From 10 Real-World Studies.
    Shen NN; Zhang C; Wang N; Wang JL; Gu ZC; Han H
    Front Pharmacol; 2021; 12():645479. PubMed ID: 33815125
    [No Abstract]   [Full Text] [Related]  

  • 25. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation combined with chronic kidney disease: a systematic review and meta-analysis.
    Li Y; Wu S; Zhou J; Zhang J
    Thromb J; 2024 Apr; 22(1):40. PubMed ID: 38679736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure: Systematic Review and Meta-Analysis of Randomized Trials.
    Raccah BH; Perlman A; Danenberg HD; Pollak A; Muszkat M; Matok I
    Chest; 2016 Jun; 149(6):1516-24. PubMed ID: 26836922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Buckley BJR; Lane DA; Calvert P; Zhang J; Gent D; Mullins CD; Dorian P; Kohsaka S; Hohnloser SH; Lip GYH
    J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35807073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Direct Oral Anticoagulants in Elderly Patients With Atrial Fibrillation: A Network Meta-Analysis.
    Deng K; Cheng J; Rao S; Xu H; Li L; Gao Y
    Front Med (Lausanne); 2020; 7():107. PubMed ID: 32318577
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients.
    Silverio A; Di Maio M; Prota C; De Angelis E; Radano I; Citro R; Carrizzo A; Ciccarelli M; Vecchione C; Capodanno D; Galasso G
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f20-f29. PubMed ID: 31830264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effectiveness and safety of DOACs vs. VKAs in treatment of left ventricular thrombus- a meta-analysis update.
    Hu T; Chen C; Maduray K; Han W; Chen T; Zhong J
    Thromb J; 2024 Mar; 22(1):23. PubMed ID: 38429631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis.
    Yang KT; Sun WC; Tsai TJ; Tsay FW; Chen WC; Cheng JS
    Int J Environ Res Public Health; 2020 Dec; 18(1):. PubMed ID: 33375495
    [No Abstract]   [Full Text] [Related]  

  • 34. Does the presence of diabetes mellitus confer an increased risk of stroke in patients with atrial fibrillation on direct oral anticoagulants? A systematic review and meta-analysis.
    Abdool M; Kunutsor SK; Khunti K; Seidu S
    Diabetes Metab Syndr; 2020; 14(6):1725-1733. PubMed ID: 32916556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct oral anticoagulants in patients with a left-sided bioprosthetic heart valve: a systematic review and meta-analysis.
    Galliazzo S; Pelitti V; Campiotti L; Poli D; Squizzato A
    Intern Emerg Med; 2023 Mar; 18(2):535-547. PubMed ID: 36746889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation.
    Raposeiras-Roubín S; Alonso Rodríguez D; Camacho Freire SJ; Abu-Assi E; Cobas-Paz R; Rodríguez Pascual C; García Comesaña J; González-Carrero López A; Cubelos Fernández N; López-Masjuán Ríos Á; Cespón-Fernández M; Muñoz-Pousa I; Caneiro-Queija B; Rodríguez Albarrán A; Castañera SÁ; Guillén JV; Carpintero Vara A; Barreiro Pardal C; Domínguez-Erquicia P; Domínguez-Rodríguez LM; Díaz Fernández JF; Fernández Vázquez F; Iñíguez-Romo A
    J Am Med Dir Assoc; 2020 Mar; 21(3):367-373.e1. PubMed ID: 31753740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation - a meta-analysis of more than 17000 patients.
    Mincu RI; Mahabadi AA; Totzeck M; Rassaf T
    Sci Rep; 2019 Feb; 9(1):3011. PubMed ID: 30816247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct Oral Anticoagulants Compared with Vitamin K Antagonists for Left Ventricular Thrombus: A Systematic Review and Meta-analysis.
    Fang S; Zhu BZ; Yang F; Wang Z; Xiang Q; Gong YJ
    Curr Pharm Des; 2022; 28(23):1902-1910. PubMed ID: 35400334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
    Salazar CA; del Aguila D; Cordova EG
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009893. PubMed ID: 24677203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.